To assess treatment effect of lower limb botulinum toxin type A (BTX-A) in combination with physiotherapy approaches on gross motor functions in children with cerebral palsy compared with only physiotherapy treatment.
OBJECTIVE:
The purpose of this review was to analyze the efficacy botulinum toxin a lower limb injections in addition to physiotherapy approaches in children with cerebral palsy.
METHODS:
A literature search was conducted in the following databases: Cochrane, PEDro, PubMed, MEDLINE, AMED and EMBASE. The searches were limited to the period from July 2009 to July 2015. The intervention had to contain BTX-A into the lower limb plus physiotherapy approaches and be compared with only physiotherapy. The methodological quality and clinical relevance were independently assessed by the authors.
RESULTS:
The database search resulted in a total of 1521 studies, of which 4 (Level II of evidence) trials were included in this review. The population represented by were age between from 11 month to 15 years. Overall there were 153 children all diagnosed with CP (87 Male, 66 Female).
CONCLUSIONS:
The use of BTX-A injections in addition to physiotherapy approaches seems to have positive effect on spasticity and ROM. However, the question of whether the treatment of BTX-A plus physiotherapy has a greater improvement on functional capacity, such as gross motor function or gait parameter than only physiotherapy treatments, was inconclusive. Further investigation by rigorous studies is required.
Ade-Hall, R., & Moore, P. (2000). Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. The Cochrane Library.
2.
Bax, M., Goldstein, M., Rosenbaum, P., Leviton, A., Paneth, N., Dan, B.,... & Damiano, D. (2005). Proposed definition and classification of cerebral palsy. Developmental Medicine & Child Neurology, 47(08), 571–576.
3.
Boyd, R. N., & Hays, R. M. (2001). Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: A systematic review. European Journal of Neurology, 8(s5), 1–20.
4.
Boyd, R. N., Edwards, P., Thorley, M., Donaghey, S., Copeland, L., Gascoignepees. L., …& Mclennan, K. (2011). Doubleblind randomized trial of intramuscular Botulinum Toxin type a and therapy compared to SHAM and therapy for care and comfort goals in children with marked bilateral cerebral palsy. Developmental Medicine and Child Neurology, 53(Suppl. 5), 3. doi: 10.1111/j.1469-8749.2011.04112.x
5.
Cans, C. (2000). Surveillance of cerebral palsy in Europe: A collaboration of cerebral palsy surveys and registers. Developmental Medicine & Child Neurology, 42(12), 816–824.
6.
Cans, C., De-la-Cruz, J., & Mermet, M. A. (2008). Epidemiology of cerebral palsy. Paediatrics and Child Health, 18(9), 393–398.
7.
Carraro, E., Trevisi, E., De Conti, C., & Martinuzzi, A. (2015). Efficacy and safety profile of incobotulinumtoxin A in children with cerebral palsy: Randomized double-blind clinical trial. Toxicon, 93, 14.
8.
Chaturvedi, S. K., Rai, Y., Chourasia, A., Goel, P., Paliwal, V. K., Garg, R. K.,... & Rathore, R. K. (2013). Comparative assessment of therapeutic response to physiotherapy with or without botulinum toxin injection using diffusion tensor tractography and clinical scores in term diplegic cerebral palsy children. Brain and Development, 35(7), 647–653.
9.
Colovic, H., Dimitrijevic, L., Lazic, L., & Marinkovic, O. (2010). Effect of botulinum toxin treatment in children with spastic cerebral palsy. European Journal of Paediatric Neurology, 14(6), 548–549.
10.
Colovic, H., Dimitrijevic, L., Stankovic, I., Nikolic, D., & Radovic-Janosevic, D. (2012). Estimation of botulinum toxin type A efficacy on spasticity and functional outcome in children with spastic cerebral palsy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 156(11), 41–47.
11.
Cucu, T., Nacu, A., & Siric, A. (2011). First experience of using botulinum toxin in treatment of spastic cerebral palsy in the republic of moldova. European Journal of Neurology, 18, 146.
12.
Darrah, J., Hickman, R., O'Donnell, M., Vogtle, L., & Wiart, L. (2008). AACPDM methodology to develop systematic reviews of treatment interventions (Revision 1.2).Milwaukee, WI, USA: American Academy for Cerebral Palsy and Developmental Medicine. 1–30.
13.
de Souza, M. E., Duarte, N. A. C., Franco, R. C., Secco, M. F. M., Politti, F., & Oliveira. C. S. (2014). Effect of Botulinum Toxin a on Spasticity and Function in Children with Cerebral Palsy: A Systematic Review. Medical Science and Technology, 55, 11–15.
14.
Druschel, C., Althuizes, H. C., Funk, J. F., & Placzek, R. (2013). Off label use of botulinum toxin in children under two years of age: A systematic review. Toxins (Basel), 5(1), 60–72.
15.
Erbguth, F. J. (2008). From poison to remedy: The chequered history of botulinum toxin. Journal of Neural Transmission, 115(4), 559–565.
16.
Franki, I., Desloovere, K., De Cat, J., Feys, H., Molenaers, G., Calders, P., …& Vanderstraeten, G. (2012). The evidencebase for basic physical therapy techniques targeting lower limb function in children with cerebral palsy: A systematic review using the International Classification of Functioning, Disability and Health as a conceptual framework. Journal of Rehabilitation Medicine, 44(5), 385–395.
17.
Garcia, Salazar, L. F., dos Santos, G. L., Pavao, S. L., Rocha, N. A., & de Russo, T. L. (2015). Intrinsic properties and functional changes in spastic muscle after application of BTX-A in children with cerebral palsy: Systematic review. Dev Neurore-habil, 18(1), 1–14.
18.
Heinen, F., Desloovere, K., Schroeder, A. S., Berweck, S., Borggraefe, I., van Campenhout, A., …& Andersen, G. L. (2010). The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol, 14(1), 45–66.
19.
Himmelmann, K., Ahlin, K., Jacobsson, B. O., Cans, C., & Thorsen, P. (2011). Risk factors for cerebral palsy in children born at term. Acta Obstetricia et Gynecologica Scandinavica, 90(10), 1070–1081.
20.
Himpens, E., Van den Broeck, C., Oostra, A., Calders, P., & Vanhaesebrouck, P. (2008). Prevalence, type, distribution, and severity of cerebral palsy in relation to gestational age: A metaanalytic review. Developmental Medicine & Child Neurology, 50(5), 334–340.
21.
Howard, J., Soo, B., Graham, H. K., Boyd, R. N., Reid, S., Lanigan, A.,… & Reddihough, D. S. (2005). Cerebral palsy in Victoria: Motor types, topography and gross motor function. Journal of paediatrics and child health, 41(9-10), 479–483.
22.
Kuzmina, N., Rafikova, Z., Yuldashev, I., & Sakhieva, L. (2011). Treatment with botulinum toxin type-a injection in children with cerebral palsy. European Journal of Neurology, 18, 147.
23.
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., … & Clarke, M. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Medicine, 6(7), 1–28.
24.
Liu, J. J., Ji, S. R., Wu, W. H., Zhang, Y., Zeng, F. Y., & Li, N. L. (2014). The relief effect of botulinum toxin-A for spastic iliopsoas of cerebral palsy on children. Eur Rev Med Pharmacol Sci, 18(21), 3223–3228.
25.
Lundy, C. T., Doherty, G. M., & Fairhurst, C. B. (2009). Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy. Dev Med Child Neurol, 51(9), 705–710.
26.
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). RESEARCH METHODS & REPORTING-Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement-David Moher and colleagues introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses. BMJ (CR)-print, 338(7716), 332.
27.
Navarrete, A., Peters, D., & Ruz, S. (2010). Functional outcome of multilevel botulinum toxin infiltration of the lower limbs and comprehensive therapy in children with spastic cerebral palsy. Rehabilitacion, 44(3), 236–243.
28.
Nolan, K. W., Cole, L. L., & Liptak, G. S. (2006). Use of botulinum toxin type A in children with cerebral palsy. Physical Therapy, 86(4), 573–584.
29.
Novak, I., McIntyre, S., Morgan, C., Campbell, L., Dark, L., Morton, N., …& Stumbles, E. (2013). A systematic review of interventions for children with cerebral palsy: State of the evidence. Dev Med Child Neurol, 55(10), 885–910.
30.
Oskoui, M., Coutinho, F., Dykeman, J., Jette, N., & Pringsheim, T. (2013). An update on the prevalence of cerebral palsy: A systematic review and meta-analysis. Developmental Medicine & Child Neurology, 55(6), 509–519.
31.
Palisano, R. J., Rosenbaum, P., Bartlett, D., & Livingston, M. H. (2008). Content validity of the expanded and revised Gross Motor Function Classification System. Developmental Medicine & Child Neurology, 50(10), 744–50.
32.
Pandyan, A. D., Gregoric, M., Barnes, M. P., Wood, D., Wijck, Fv., Burridge, J., …& Johnson, G. R. (2005). Spasticity: Clinical perceptions, neurological realities and meaningful measurement. Disability & Rehabilitation, 27(1-2), 2–6.
33.
Pin, T. W., Elmasry, J., & Lewis, J. (2013). Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: A systematic review. DevMed Child Neurol, 55(4), 304–13.
34.
Ponten, E. (2013). Botulinum toxin injections in lower extremities increase physical activity in upper extremities in children with cerebral palsy. Developmental Medicine and Child Neurology, 55, 10.
35.
Rodrigues, D. B., Assis, T. S., & Santos, L. C. (2010). Comparison between clinical evaluation and quality of life in a pediatric population with cerebral palsy treated with botulinum toxin type A. Annals of Neurology, 68, 120.
36.
Rosenbaum, P., Paneth, N., Leviton, A., Goldstein, M., Bax, M., Damiano, D., … & Jacobsson, B. (2007). A report: The definition and classification of cerebral palsy April 2006. Dev Med Child Neurol (Suppl, 109), 8–14.
37.
Rosenbaum, P. L., Palisano, R. J., Bartlett, D. J., Galuppi, B. E., & Russell, D. J. (2008). Development of the Gross Motor Function Classification System for cerebral palsy. Developmental Medicine & Child Neurology, 50(4), 249–253.
38.
Russell, D. J., Rosenbaum, P. L., Avery, L. M., & Lane, M. (2002). Gross motor function measure (GMFM-66 and GMFM-88) user's manual: Cambridge University Press.
39.
Ryll, U., Bastiaenen, C., De Bie, R., & Staal, B. (2011). Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: A systematic review. Developmental Medicine and Child Neurology, 53(3), 210–216.
40.
Sanger, T. D., Delgado, M. R., Gaebler-Spira, D., Hallett, M., & Mink, J. W. (2003). Classification and definition of disorders causing hypertonia in childhood. Pediatrics, 111(1), e89–e97.
41.
Sankar, C., & Mundkur, N. (2005). Cerebral palsy-definition, classification, etiology and early diagnosis. The Indian Journal of Pediatrics, 72(10), 865–868.
42.
Singhi. P., & Ray, M. (2004). Botulinum toxin in children with cerebral palsy. The Indian Journal of Pediatrics, 77(12), 1087–1091.
43.
Tedroff, K., Lowing, K., Haglund-Akerlind, Y., Gutierrez-Farewik, E., & Forssberg, H. (2010). Botulinum toxin A treatment in toddlers with cerebral palsy. Acta Paediatr, 99(8), 1156–1162.
44.
Tilton, A. (2009) Management of Spasticity in Children With Cerebral Palsy. Seminars in Pediatric Neurology, 16(2), 82–89.
45.
Tilton, A., Maciag-Tymecka, I., Jozwiak, M., Unlu, E., Velez, J., Tse, A., & Picaut, P. (2015). Baseline characteristics of patients from a phase 3 program to assess abobotulinumtoxinA (Dys-port) in the treatment of spasticity and functional impairments in children with dynamic equinus foot deformity due to cerebral palsy. Toxicon, 93, 59–S60.
46.
Vander Houwen, L. E. E., Scholtes, V. A., Becher, J. G., &Harlaar, J. (2011). Botulinum toxin A injections do not improve surface EMG patterns during gait in children with cerebral palsy-A randomized controlled study. Gait and Posture, 33(2), 147–1451.
47.
Ward, A. B. (2002). A summary of spasticity management-a treatment algorithm. European Journal of Neurology, 9(s1), 48–52.
48.
Xu, K., Yan, Y., & Mai, J. (2009). A randomized controlled trial to compare two botulinum toxin injection techniques on the functional improvement of the leg of children with cerebral palsy. Clin Rehabil, 23, 800–811.
49.
Zonta, M. B., Bruck, I., Puppi, M., Muzzolon, S., Neto, Ade. C., & Coutinho dos Santos, L. H. (2013). Effects of early spasticity treatment on children with hemiplegic cerebral palsy: A preliminary study. Arq Neuropsiquiatr, 71(7), 453–461.
